Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

The case for vaccinating children under 12 against COVID-19

Researchers assess the need for coronavirus disease 2019 (COVID-19) vaccination in children who are 12 years of age or younger.

14 Nov 2021

Mycobacterium tuberculosis may induce resistance to secondary SARS-CoV-2 infection

The current study reveals that mice infected with mycobacterium tuberculosis are resistant to SARS-CoV-2 infection.

14 Nov 2021

Inflammatory cytokines may help predict patient outcomes after traumatic injury

Inflammatory cytokines are molecules that are secreted by immune cells to promote inflammation. A study published in the Journal of Orthopaedic Research found that measuring inflammatory cytokines may help predict patient outcomes after traumatic injury, which is the leading cause of mortality in individuals under 50 years of age.

3 Nov 2021

Impact of SARS-CoV-2 infection on human semen quality

A new review article aimed to extract, review and summarize these articles from the mentioned databases to determine the link between SARS-CoV-2 infection and semen quality.

3 Nov 2021

Potential link between SARS-CoV-2 infection and secondary occurrence of anti-NMDAR encephalitis

Scientists explore the link between SARS-CoV-2 infection and anti-NMDAR encephalitis.

1 Nov 2021

Sexually dimorphic placental antibody transfer during SARS-CoV-2 infection

In a paper recently published in the journal Science Translational Medicine by Bordt et al. (October 19th, 2021), maternal SARS-CoV-2 infections are studied with particular regard to maternal-fetal antibody transfer and virus-induced placental interferon responses, finding a sexually dimorphic response that results in lesser antibody transfer to the male fetus.

26 Oct 2021

Targeting SARS-CoV-2 with Chaga mushroom – a natural antiviral compound

A new study examines the potential binding interaction of the beneficial components of Chaga mushroom with that of the SARS-CoV-2 RBD.

24 Oct 2021

Chemical substance may specifically inhibit both SARS-CoV-2 proteases and human protease

Researchers tested analogs of disulfiram on SARS-CoV-2 Mpro and PLpro to find more efficient and effective inhibitors that take advantage of disulfiram’s mechanism of binding to the cysteine residue.

22 Oct 2021

Biomarker predicts severity of SARS-CoV-2 infection in patients

A new study investigates a biomarker to predict the severity of disease in patients infected with SARS-CoV-2.

20 Oct 2021

Key lessons from COVID-19 pandemic for scientific and clinical communities

In a paper published in the journal Cell, researchers have investigated and criticized clinical care management and drug administration within the pandemic.

4 Oct 2021

Persistent leukocyte changes three months after mild SARS-CoV-2 infection

A recent study discusses the rate of changes in peripheral blood white cells in individuals who have recovered from SARS-CoV-2 infection.

3 Oct 2021

WHO experts recommend antibody treatment for two specific groups of patients with covid-19

A treatment combining two antibodies (casirivimab and imdevimab) is recommended for two specific groups of patients with covid-19 by a WHO Guideline Development Group (GDG) panel of international experts and patients in The BMJ today.

24 Sep 2021

Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

In a recent study, researchers investigate the possibility of using the thiazolide antiparasitic nitazoxanide for the treatment of COVID-19.

15 Sep 2021

Deep profiling of SARS-CoV-2 immune response amongst the mildly symptomatic

In a research paper recently uploaded to the medRxiv* preprint server by Capelle et al. (September 2nd, 2021), the immune response of mild and hospitalized COVID-19 patients is compared, finding that early T-cell response is a vital indicator of SARS-CoV-2 disease severity.

15 Sep 2021

Flu shots and COVID-19 immunity

A new paper finds that the influenza vaccine may influence both the response to and incidence of infection by the SARS-CoV-2.

14 Sep 2021

Metabolic and immune markers as tools for risk stratification and monitoring in COVID-19

In a new study posted to the medRxiv* server scientists from Weil Cornell University and Stony Brook University in New York attempted to identify the metabolic and immune markers associated with severe COVID-19 disease using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. This will facilitate risk stratification, monitoring, and therapeutic interventions in COVID-19 patients.

14 Sep 2021

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

Research uncovers test to identify iMCD patients with superior response to FDA-approved treatment

New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.

2 Sep 2021

Newly discovered cell type makes survivors of sepsis more vulnerable to infections

Sepsis is the leading cause of death in Brazil's intensive care units (ICUs). Among patients who progress to the severe form of the disease, 40% die, and the survivors often suffer from cardiovascular and neurological complications, as well as a significant decline in immunity lasting for years after they are discharged from hospital.